Ynvisible Interactive Inc., a leader in printed e-paper display technology, has received a Letter of Intent from Sapphiros, a privately held consumer diagnostics company, to establish Ynvisible as an exclusive supplier of displays for certain lateral flow and molecular diagnostic tests manufactured by Sapphiros.
Key highlights
- FDA regulatory pathway underway: Clinical studies of Sapphiros’ Digital Lateral Flow tests are underway.
- Exclusive supply agreement expected: LOI outlines intention to enter into a three‑year exclusive supply agreement.
- Commercial sales in 2026: Sales of Ynvisible displays to Sapphiros are underway and will accelerate throughout 2026.
- Expanding medical diagnostics market: This partnership represents Ynvisible’s first commercial business in the large and rapidly growing global sector of Medical Diagnostics, with the Company expecting other customers in this market.
To date, Ynvisible has supplied Sapphiros’ companies with displays for laboratory testing and ongoing clinical studies related to platforms for respiratory and other rapid diagnostic tests, which are designed for both the point-of-care and direct-to-consumer markets. The LOI anticipates continued supply of Ynvisible products in support of the commercial launch of Sapphiros’ products, once they receive regulatory approval.
This milestone builds on joint development work that began in 2024, during which Ynvisible engineered customised display solutions for integration into Sapphiros’ diagnostics platforms.
Strategic significance
The agreement represents an important step in Ynvisible’s strategy to expand into high-volume medical and diagnostic applications, a market that continues to expand as healthcare systems increasingly adopt decentralised testing and rapid diagnostic technologies. Ynvisible’s ultra-low power, thin, and flexible displays deliver clear, reliable results and are capable of operating without complex electronics, making Ynvisible’s technology particularly well-suited for these applications.
“This Letter of Intent represents an important step toward commercial deployment of Ynvisible’s technology in next-generation diagnostic devices,” said Ramin Heydarpour, CEO and Chairman of Ynvisible. “Our collaboration with Sapphiros demonstrates the performance and scalability of our printed e-paper displays in medical applications. As Sapphiros advances toward regulatory approvals and prepares for commercial launch, this relationship has the potential to create significant high-volume opportunities for Ynvisible.”
“Sapphiros is committed to delivering innovations in diagnostics that enable global access and equitable health outcomes to patients and providers alike,” said Mark Gladwell, CEO of Sapphiros. “Our partnership with Ynvisible empowers users of our diagnostic devices, whether in their homes, in clinical settings or elsewhere, with clear, visible results, offering confidence in understanding test outcomes.”